biosimilars

Research Reports

08/15/2022

Stephen Hamilton, MD

Kathryn Christensen, MS

Margaret Rausa, PharmD

Nick Andrews, PharmD

Timothy Dollear, MS

Christopher Linkimer, CPA

Eric Gratias, MD, FAAP

Dr Hamilton and colleagues outline how eviCore Healthcare offered the option for payer clients to implement a biosimilar preferencing policy, analyzing how this policy affected the rate of biosimilar use and costs.

Dr Hamilton and colleagues...

08/15/2022

Journal of Clinical Pathways

News

First-Line Biosimilar-Based Triplet Effective in HER2-Positive Gastric Cancer

07/08/2020

A first-line triplet regimen consisting of pembrolizumab, biosimilar trastuzumab (Herzuma), and chemotherapy is effective in patients with HER2-positive advanced gastric cancer, according to the results of a phase...

A...

07/08/2020

Journal of Clinical Pathways

News

Cost Savings of Supportive Care Biosimilar in the Medicare OCM Population

06/12/2020

A new study sought to better understand how The Centers for Medicare and Medicaid Services (CMS) reimbursement for pegfilgrastim has been impacted by the introduction of two pegfilgrastim biosimilars into the...

A new...

06/12/2020

Journal of Clinical Pathways

Clinical Pathways GPS

The Place for Biosimilars in Clinical Pathways

12/14/2015

Richard G. Stefanacci, DO, MGH, MBA, AGSF, CMD

Scott Guerin, PhD

Payers and at-risk providers are developing clinical pathways with great specificity regarding the preferred drugs that be used. Increasingly, these pathways will include biosimilar products. There are three major...

Payers...

12/14/2015

Journal of Clinical Pathways